In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-19 of 19 for your search:

Drug:  recombinant interferon alfa
Find trials that include:  Any drugs shown
Trial Status:  Active

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase III Randomized Study of Imatinib Mesylate Alone or With Interferon alfa or Low-Dose Cytarabine Versus Interferon alfa Standard Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: III-MK-CML-IV, EU-20248, NCT00055874

SU011248 versus Interferon-alfa as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181034, UCLA-0406015-01, PFIZER-A6181034, NCT00083889

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: MCL2004-1, NCT00209209

Phase III Randomized Study of Intravesical Mitomycin C and Bladder Hyperthermia Versus Intravesical Bacillus Calmette-Guerin (BCG) or Standard Therapy as Second-Line Therapy in Patients With Recurrent Non-Muscle Invasive Bladder Cancer After Induction or Maintenance BCG

Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CRC-TU-BL3010-HYMN, CRCTU-BL3010-HYMN, ISRCTN85785327, EUDRACT-2008-005428-99, EU-21015, UCL-08/0365, KYOWA-CRC-TU-BL3010-HYMN, MREC-09/H0717/56, NCT01094964

Phase I/II Study of Cisplatin, Gemcitabine, Interferon alfa, and Long-Duration, Low-Temperature Whole Body Hyperthermia (LL-WBH) in Patients with Advanced Malignancies

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UTHSC-MS-99116, NCI-V99-1561, NCT00004063

Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: immatureDC- HMO-CTIL, NCT00278018

Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Luc 10-002, NCT01191034

Phase II Study of Interferon alfa in Patients With Grade I, II, or III Lymphomatoid Granulomatosis and of Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab in Patients With Grade III Lymphomatoid Granulomatosis

Phase: Phase II
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: NCI
Protocol IDs: NCI-94-C-0074, NCI-MB-325, NCT00018993

Phase II Study of Cisplatin, Metronomic Low-Dose Interferon alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Patients With Inoperable or Metastatic Pancreatic Cancer

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UTHSC-MS-02117, NCT00082862

10.

Immunochemotherapy for Metastatic Renal Cell Carcinoma

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 1747CTIL, Raphael Rubinov, NCT00226798

11.

Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: No age specified
Sponsor: Other
Protocol IDs: HSC-MS-04-259, NCT00178698

12.

Imatinib Mesylate, Interferon Alfa, and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: J05121 CDR0000492005, P30CA006973, JHOC-J05121, J05121, NCT00363649

13.

Rituximab and CVP Plus Interferon for Follicular Non Hodgkins Lymphoma (NHL)

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: LNH-Pro-05, EudraCT Number:2005-004761-42, NCT00842114

14.

Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors

Phase: Phase II
Type: Treatment
Status: Active
Age: 12 to 70
Sponsor: Other
Protocol IDs: 0457-08-HMO-CTIL, NCT00855452

15.

NAM-Trial: Multiferon in Malignant Melanoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 5021000, NCT01341158

16.

Determining the Maximum Tolerated Dose of Low Dose Interferon-alfa in Conjunction With Nilotinib in Imatinib Resistant and/or Intolerant Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)

Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107ADE10, EudraCT 2010-022006-40, NCT01220648

17.

Pilot Study of High Throughput Protein Profiling Analysis in Patients With High-Risk Melanoma Undergoing High-Dose Interferon Therapy

Phase: No phase specified
Type: Biomarker/Laboratory analysis
Status: Approved-not yet active
Age: Not specified
Sponsor: NCI
Protocol IDs: ECOG-E1694T1, E1694T1, NCT00897520

18.

Quality of Life and Psychological Well-being in Patients With Malignant Melanoma

Phase: No phase specified
Type: Natural history/Epidemiology, Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PO5098, NCT00963261

19.

The Effect of Postoperative Interferon- Alpha Treatment in Low miR-26 Expression Patients With HCC